- Company
- 2nd generation EGFR TKI Vizimpro can be prescribed in Big 5
- by Eo, Yun-Ho Jul 6, 2022 05:47am
- Pfizer's second-generation EGFR TKI Vizimpro has settled in the Big 5 General Hospital. According to related industries, Pfizer's EGFR TKI Vizimpro recently passed all five major medical institutions such as Samsung Medical Center, Seoul National University Hospital, Seoul St. Mary's Hospital, Asan Medical Center, and Sinchon Severance Hospit
- Company
- There are many complaints about the revaluation of generics
- by Chon, Seung-Hyun Jul 6, 2022 05:46am
- Pharmaceutical companies complain of unnecessary waste of money on products being sold without problems. Pharmaceutical companies are struggling ahead of the general drug price revaluation. There are many concerns that the biological equivalent test, which was conducted with the aim of maintaining drug prices, could lead to a reduction in dru
- Company
- Sanofi & MDsquare co-promote Digital Healthcare Business
- by Jul 5, 2022 05:58am
- Sanofi Korea Corporation announced on the 4th that it held a (MOU) signing ceremony with MDsquare to promote digital healthcare business on the 30th of last month. With this agreement, Sanofi provides chronic disease management and prevention information, and MDsquare develops premium health care programs to cooperate so that patients with
- Company
- RDK introduces monkeypox PCR test kits to Korea
- by Jul 5, 2022 05:58am
- On the 4th, Roche Diagnostics Korea announced that it had introduced PCR diagnostics kits for the detection of the monkeypox virus in Korea. The three kits that were introduced to Korea this time -▲ LightMix Modular Orthopox Virus, ▲ LightMix Modular Monkeypox Virus, and ▲ LightMix Modular Orthopox Virus typing1- were developed by Roch
- Company
- CKD voluntarily discontinues P3T on its COVID-19 therapy
- by Kim, Jin-Gu Jul 4, 2022 05:55am
- Chong Kun Dang issued a public notice on the 1st that it will discontinue the Phase III trial on its CKD-314 (Nafabeltan Inj.) it had been developing as a COVID-19 treatment. Chong Kun Dang explained, “We found it difficult to conduct a clinical trial to identify the patients’ rate of progression to severe disease due to the reduced inc
- Company
- Lotte Biologics cooperates with Sigma
- by Jul 4, 2022 05:54am
- Lotte Biologics announced on the 1st that it has signed a business agreement with Millipore Sigma, Merck's North American life science division to strengthen its bio business capabilities. With this agreement, the two companies will cooperate in promoting new biopharmaceutical businesses such as next-generation treatments and expanding Syr
- Company
- Tdap vaccine Adacel can be prescribed in general hospitals
- by Eo, Yun-Ho Jun 30, 2022 05:53am
- Sanofi Pasteur's new Tdap vaccine Adacel can be prescribed in general hospitals. According to related industries, the Tdap vaccine for teenagers and adults aged 11 or older has passed the DC of 100 medical institutions, including Seoul National University Hospital, Korea University Guro Hospital, Gangbuk Samsung Hospital, and Hallym Univer
- Company
- 16 companies including Amgen launch industrial union
- by Eo, Yun-Ho Jun 30, 2022 05:52am
- A new confederation of unions centered around multinational pharmaceutical companies is soon to be launched in Korea. According to industry sources, a National Pharmaceutical & Bio Labor Union (NPU) under the Federation of Korean Trade Unions will be launched on July 5th. Labor unions of 16 companies, including labor unions from Korea
- Company
- 2nd P-CAB Fexclu to be released into the 800 bil market
- by Chon, Seung-Hyun Jun 30, 2022 05:52am
- Daewoong Pharmaceutical’s new drug, ‘Fexclu’ will be released next month. The industry’s eyes are on whether the drug will raise a storm in the PPI class and P-CAB class antiulcer medication prescription market that is estimated to be worth over &8361;800 billion. The industry is also eyeing competition between Fexclu and K-CAB abroad.
- Company
- Opdivo reattempts reimb in first-line gastric cancer
- by Eo, Yun-Ho Jun 29, 2022 05:54am
- The cancer immunotherapy drug Opdivo is reattempting reimbursement as a first-line treatment once more. According to industry sources, Ono Pharma Korea and BMS Korea’s PD-1 inhibiting cancer immunotherapy Opdivo (nivolumab) will be deliberated by the Cancer Disease Deliberation Committee (CDDC) of the Health Insurance Review and Assessm
